Making Science Work at CPhI Worldwide 2019
CPhI Worldwide now comprises six individual pharma events and more than 20 dedicated zones.
List view / Grid view
CPhI Worldwide now comprises six individual pharma events and more than 20 dedicated zones.
The FDA has given a complete response letter to AstraZeneca for its PT010 treatment, regarding its New Drug Application.
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
A survey of pharmacists has discovered that UK pharmacies experienced shortages across all 36 medicine categories in the last six months.
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
Large-value deals are a new strategy for stakeholders to capitalise on the strengths of other companies and to overcome barriers to financial success.
Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery.
Rituxan (rituximab) is the first approved treatment for children with rare vasculitis diseases, in which a patient’s small blood vessels become inflamed.
The UK National Audit Office has released a report which has found that medicine supply to the UK will be delayed in the event of a no-deal Brexit.
Research has found that the pharmaceutical industry in India must encourage innovation in order to keep up with the growth of the sector.
The European Medicines Agency has issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
The probable carcinogen N-nitrosodimethylamine was detected in Sandoz’s ranitidine capsules, prompting the voluntary move.
Researchers have developed a chikungunya vaccine that can be stored at warm temperatures and manufactured quickly, which has been validated in animal models.